Biogen will soon launch an open-label trial to start re-dosing aducanumab — an injectable treatment under development — to patients with Alzheimer’s disease who participated in four studies halted in March 2019. The company said it submitted the protocol of the re-dosing study to the U.S.
Researchers have discovered a likely reason why the most common form of the CD33 protein is a risk factor for Alzheimer’s disease, a finding that could open new therapeutic avenues targeting the protein, a study reports.
[Editor’s note: This story, published on Dec. 10, was updated on Dec. 16 with additional details provided by Acadia Pharmaceuticals.] People with Alzheimer’s and other dementias treated with Nuplazid (pimavanserin) in a Phase…
Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of mild to moderate Alzheimer’s disease (AD) has fully enrolled more than 700 patients. The T2 Protect AD trial will assess if troriluzole use can protect against or slow…
The second part of a clinical study evaluating the use of a blood diagnostic test for Alzheimer’s disease — called the Lymphocyte Proliferation Test (LymPro Test) — is now fully enrolled, the trial’s sponsor, Breakthrough Diagnostics, announced. The trial is ongoing at Leipzig University in Germany, and top-line results…
Biogen is planning to seek approval for aducanumab, an injectable treatment under investigation for patients with early Alzheimer’s disease, following a new analysis of Phase 3 studies supporting meaningful benefits for patients’ cognition and daily life abilities. After meeting with the U.S. Food and Drug Administration…
Genentech, a subsidiary of Roche, has launched a new substudy to learn more about the progression of early-onset familial Alzheimer’s disease, as part of its ongoing Alzheimer’s Prevention Initiative (API)…
Alzheimer’s oral therapy candidate PRI-002, being developed by Priavoid, has proven safe for human use in healthy volunteers during a Phase 1 clinical trial. These positive trial results provide important evidence that supports progressing…
Elenbecestat and BAN2401, two potential anti-amyloid therapies, were selected by the Alzheimer’s Clinical Trials Consortium (ACTC) to be evaluated in clinical studies aiming to prevent progression to early stages of Alzheimer’s disease.
An online program that teaches how to focus on positive emotions can help caregivers of family members with dementia to cope better with stress, and reduce their depression and anxiety symptoms, results from a clinical study suggest. The six-week skill-building intervention, called Life Enhancing Activities for…
Get regular updates to your inbox.